Increased Hemoglobin With SGLT2 Inhibitors

Дата публикации: 24-10-2026 00:00:00

Inhibitors of the sodium-glucose transporter 2 (SGLT2i) were developed to improve metabolic control of diabetes by inducing urinary glucose excretion. When tested for cardiovascular safety, use of SGLT2i surprisingly showed improvements in cardiovascular and kidney outcomes. SGLT2 inhibitors have now become firmly established as guideline-recommended therapy in patients with diabetes and high cardiovascular risk, in patients with heart failure, and in those with chronic kidney disease (CKD).

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	SGLT2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron, and Erythropoiesis	0	15.52	24-10-2026
2	Создан очищающий кровоток от излишков глюкозы имплантат для диабетиков	0	7.79	22-10-2026
3	Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM	5	7	02-07-2026
4	Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials [version 1; peer review: awaiting peer review]	0	8.78	06-08-2026
5	«СОГАЗ‑Мед»: ваш надёжный помощник в профилактике и контроле сахарного диабета по ОМС	0	8.59	28-08-2026
6	GLP-1 Medications May Improve Health in People With PAD and Diabetes	0	9.88	18-08-2026
7	ما تفعله مساء يظهر أثره وأنت نائم.. انتبه لسكر الدم	0	9.59	14-09-2026
8	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	2	7	31-07-2025
9	Once-daily inhaled mosliciguat yields improvements in PH-ILD	0	16.09	09-10-2026
10	Диабет назвали фактором риска тяжёлого гриппа	0	8.21	25-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.58. Источник: www.jamanetwork.com.